SCHEMBL1557791

SCHEMBL1557791

CNC(=O)c1ccccc1Nc1cc(Nc2cn(C)nc2C)ncc1C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 10/20 0.65
MAPK10 P53779 10/20 0.65
MAPK3 P27361 2/20 0.57
MAPK1 P28482 2/20 0.57
PTK2 Q05397 3/20 0.57
TYK2 P29597 5/20 0.46
JAK1 P23458 4/20 0.46
JAK2 O60674 3/20 0.46
CYP1A2 P05177 1/20 0.46
LRRK2 Q5S007 1/20 0.46
PDE4D Q08499 1/20 0.46
KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1557859 0.91 MAPK9 (0.64) MAPK9MAPK10MAPK3MAPK1PTK2
SCHEMBL1559071 0.91 MAPK9 (0.64) MAPK9MAPK10MAPK3MAPK1PTK2
SCHEMBL1558835 0.90 MAPK10 (0.54) MAPK9MAPK10MAPK3MAPK1PTK2
SCHEMBL1558635 0.90 MAPK3 (0.61) MAPK9MAPK10MAPK3MAPK1PTK2
SCHEMBL1557835 0.90 MAPK3 (0.54) MAPK9MAPK10MAPK3MAPK1PTK2
SCHEMBL2182698 0.89 MAPK10 (0.65) MAPK9MAPK10MAPK3MAPK1PTK2
SCHEMBL1557997 0.89 MAPK10 (0.61) MAPK9MAPK10MAPK3MAPK1PTK2
SCHEMBL1559391 0.89 MAPK3 (0.73) MAPK9MAPK10MAPK3MAPK1PTK2
SCHEMBL1558772 0.88 MAPK9 (0.54) MAPK9MAPK10MAPK3MAPK1TYK2
SCHEMBL12413820 0.88 MAPK10 (0.60) MAPK9MAPK10MAPK3MAPK1PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011524411-A 2011-09-01 JP claimed
CN-102124000-A Pyridine compounds ASTRAZENECA AB 2011-07-13 CN claimed
US-20110166139-A1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2011-07-07 US claimed
EP-2303861-A1 PYRIDINE COMPOUNDS AstraZeneca AB (SE) 2011-04-06 EP claimed
WO-2009153589-A1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2009-12-23 WO claimed
CN-102124000-B Pyridine compounds ASTRAZENECA AB 2014-09-17 CN disclosed
EP-2303861-B1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2014-04-23 EP disclosed
US-8569298-B2 Pyridine compounds ASTRAZENECA AB (SE) 2013-10-29 US disclosed
CN-102124000-A Pyridine compounds ASTRAZENECA AB 2011-07-13 CN disclosed
US-20110166139-A1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2011-07-07 US disclosed
EP-2303861-A1 PYRIDINE COMPOUNDS AstraZeneca AB (SE) 2011-04-06 EP disclosed
WO-2009153589-A1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166139-A1 PYRIDINE COMPOUNDS PTK2, PTK2B, PFKP MAPK9 217/4885MAPK10 301/4885MAPK3 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.